ms101phd

대전서 구토·발열 등으로 50여 명 결석…노로바이러스 검출 #KBS #KBS뉴스 news.kbs.co.kr/news/pc/view/v…

$COCP New 13F May 8, 2026 Vanguard brand new position Vanguard Capital: 239,971 sh Vanguard Trust: 24,016 sh This is the start of first meaningful new institutional buying seen in years. It’s still a small position for but in $20M mc with a tiny real float, 264k sh is noticeable

More than 100 people have been sickened in a norovirus outbreak on board a Caribbean Princess cruise, according to the CDC. abcnews.link/NFXWCpR

$COCP Fresh Norovirus outbreak on the Caribbean Princess 115 people sick (102 passengers + 13 crew). The ship is still at sea in the Caribbean until May 11. While the entire world is glued to the Hantavirus cruise panic, the far more common cruise ship killer just struck again. No approved antiviral exists. Cocrystal’s oral CDI-988 has FDA Fast Track and is in active Phase 1b human challenge trials built specifically for these repeated outbreaks. Years of BARDA/RRPV + DOD positioning with Fred Hassan on the board. cruiselawnews.com/2026/05/articl…

$COCP 300+ people sickened by Norovirus in Sweden two sushi restaurants shut down after the outbreak. This highly contagious bug is exploding on land and at sea with zero approved treatments. Cocrystal’s oral CDI-988 now has FDA Fast Track and is in active Phase 1b trials. Strong BARDA/RRPV + DOD setup with Fred Hassan on the board. Funding catalyst coming soon. foodsafetynews.com/2026/05/norovi…

$COCP Hantavirus killed 3 on MV Hondius cruise ship possible human to human spread. Norovirus is the real cruise ship killer: CDC reported 23 GI outbreaks in 2025, all Norovirus. No approved antiviral exists. Cocrystal’s CDI-988 just got FDA Fast Track + active Phase 1b trials. BARDA/RRPV + DOD positioning + Fred Hassan on board. Funding surprise catalyst incoming. theconversation.com/hantavirus-cov…

JUST IN - A virus outbreak on a cruise ship leaves 3 people dead, and 5 more suspected cases, the cause is being investigated with one case of Hantavirus confirmed — Sky

$COCP ICAR just dropped Slide 15 confirms: Phase 1b Norovirus challenge study at Emory is actively enrolling. First cohort is now fully enrolled and the first dose with the GII.2 challenge virus has been administered. This is the first public confirmation that the human challenge trial is moving forward cleanly. CDI-988 remains the only oral antiviral in the world for Norovirus treatment and prevention. Full deck: content.equisolve.net/_ea82782fa32ec…

$COCP Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection cocrystalpharma.com/news/press-rel…

$COCP April 15 Short Interest just printed: 988,346 shares. That’s +839,435 new shorts added in the past 2 weeks alone a 564% explosion. Since the April 15 settlement (last 9 trading days), shorts have kept piling in even more. Real short position is now well over 1.2 million shares (22-25% of the real tradable float) and still growing. Borrow rate still sitting at 206%.

$COCP at close today: S-3 shelf filing = nothing burger, just standard paperwork •Borrow rate still 210.73% •Shares available locked at only 80k all day (never loosened like usual) •Short Interest report (April 15 settlement) drops tomorrow

“UKHSA warning: Norovirus is no longer seasonal it’s year-round now." $COCP has the first and only oral drug for treatment and prevention. cambridge-news.co.uk/news/health/uk…

$COCP Full author list includes the entire Cocrystal leadership team + key consultants. This is Fred Hassan’s 3 year quiet derisk playbook reaching the premier antiviral research conference in the world. The street is still asleep on this blue ocean blockbuster. virtual.oxfordabstracts.com/event/public/7…

$COCP ICAR 2026 schedule is now official. Thursday, April 30 at 5:15 PM Title: First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Novel Mechanism of Action and Phase 1 Study Results Presenter: Sam Lee, Ph.D. President & co-CEO This is the first public scientific presentation of CDI-988 Phase 1 results + initial data from the ongoing Phase 1b challenge study.

$COCP Borrow rate held strong the entire week at 276% the truth teller. Days-to-cover has exploded to 12.9 days while shorts keep pinning the stock lower on light volume. Major catalysts stacked this month: ICAR presentation in only 16 days + Fred Hassan’s 3-year non-dilutive BARDA pursuit. The fuse just keeps getting longer…......

$COCP Pressure keeps building. But the part that hasn’t changed shorts are still not covering the big short and every single day they stay short they’re bleeding tens of thousands of dollars in borrow fees current 277.71% with only a few thousand shares available on the desk. This is the exact light-volume pin job. Shorts look like they’re winning today because volume is garbage, but they’re just delaying the inevitable on a massive trapped position. The second volume wakes up even 1M+ shares or any catalyst hits, the covering wave on 7.5M–8M short starts and it snowballs fast on the 9.1M float.

$COCP 271% borrow rate + only 15k shares available. Max short now 7.5M–8M (85–90% of 9.1M float) retail locked the rest post FDA new. Shorts still pinning it under $1.50 on low volume but they’re getting torched daily on fees. This is primed to explode.

1/ 📈 WWSCAN Weekly Data Respiratory & Gastrointestinal Weekly Update: Influenza A, Influenza B, RSV, HMPV, Norovirus, and Rotavirus are in the high category. SARS-CoV-2 is in the medium category. EV-D68 is in the ‘Low’ category nationwide.

$COCP New Medscape data (today): By age 2, **90% of US infants** have already had an enteric viral infection. **Norovirus GII** has the *highest* rate of symptomatic acute gastroenteritis (.4 cases per child year) now the leading cause post-rotavirus vaccine. No approved treatments or vaccines exist. Cocrystal’s CDI-988 (oral 3CL protease inhibitor, Fast Track) is in Phase 1b for both treatment **and** prevention. Huge unmet need just got clearer. Article: medscape.com/viewarticle/mo…

$COCP Creeping up now 289.15% last it is exactly what happens when availability collapses to 900 shares. Might go nuclear with 75-100% float short.

$COCP PRESSURE COOKER. Classic held down by shorts at close spiked to $1.56 in last 10m shows shorts had to work to keep it from closing stronger on lite vol. Immediate short response is exactly what you see when shorts are trapped. Borrow desk still record territory 281%.